

## DESCRIPTION


<b>Species Reactivity</b>	Rat
<b>Specificity</b>	Detects rat IL-18/IL-1F4 in direct ELISAs and Western blots. In Western blots, approximately 35% cross-reactivity with recombinant mouse IL-18 is observed and approximately 10% cross-reactivity with recombinant human IL-18 is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant rat IL-18/IL-1F4 His37-Ser194 Accession # P97636
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	0.1 µg/mL	Recombinant Rat IL-18/IL-1F4 (Catalog # 521-RL)
<b>Neutralization</b>		Measured by its ability to neutralize IL-18/IL-1F4-induced IFN-γ secretion in activated mouse T cells [Ahn, H.J. <i>et al.</i> (1997) <i>J. Immunol.</i> <b>159</b> :2125]. The Neutralization Dose (ND <sub>50</sub> ) is typically 1-3 µg/mL in the presence of 15 ng/mL Recombinant Rat IL-18/IL-1F4 and 0.1 ng/mL Recombinant Mouse IL-12.

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Interleukin-18 (IL-18), also known as IL-1F4 and IFN- $\gamma$  inducing factor (IGIF), is a member of the IL-1 family of cytokines and is a key molecule in the innate immune response (1). Rat IL-18 is synthesized as a 24 kDa proprotein that contains a 36 amino acid (aa) propeptide and a 158 aa mature region (2). Under inflammatory conditions, the propeptide is cleaved by Caspase-1 in the cytoplasm to liberate the mature nonglycosylated 18 kDa monomeric IL-18 (3, 4). Mature rat IL-18 shares 91% aa sequence identity with mouse IL-18 and 60-64% aa sequence identity with human, canine, feline, porcine, and rhesus macaque IL-18. IL-18 is secreted by a variety of cell types including macrophages, dendritic cells, and epithelial cells (1, 5). Circulating mature IL-18 is sequestered by soluble IL-18 binding proteins (IL-18 BP) that inhibit IL-18 bioactivity (6). IL-18 interacts with the widely expressed IL-18 R $\alpha$  which then recruits the signaling subunit IL-18 R $\beta$  (7, 8). The IL-1 family member IL-1F7 also binds to IL-18 R $\alpha$  but does not recruit IL-18 R $\beta$  or induce signaling (9). IL-1F7 binds IL-18 BP and enhances its neutralizing effect on IL-18 activity (9). IL-18 synergizes with other cytokines to activate NK, Th1, and Th17 cells and to increase the production of IFN- $\gamma$  (1, 5, 10-12). IL-18 can also promote Th2 cytokine release which reduces the effectiveness of antiviral responses (13, 14). Increased levels of active IL-18 contribute to the severity of autoimmunity and hypertension, while deficiency of IL-18 results in symptoms of metabolic syndrome (1, 5, 15, 16). In cancer, IL-18 stimulates Th1 and NK cells to target tumor cells, but it can also promote angiogenesis, metastasis, and tumor cell immune evasion (11).

**References:**

1. Arend, W.P. *et al.* (2008) *Immunol. Rev.* **223**:20.
2. Culhane, A.C. *et al.* (1998) *Mol. Psychiatry* **3**:362.
3. Ghayur, T. *et al.* (1997) *Nature* **386**:619.
4. Gu, Y. *et al.* (1997) *Science* **275**:206.
5. Boraschi, D. and C.A. Dinarello (2006) *Eur. Cytokine Netw.* **17**:224.
6. Novick, D. *et al.* (1999) *Immunity* **10**:127.
7. Torigoe, K. *et al.* (1997) *J. Biol. Chem.* **272**:25737.
8. Born, T.L. *et al.* (1998) *J. Biol. Chem.* **273**:29445.
9. Bufler, P. *et al.* (2002) *Proc. Natl. Acad. Sci. USA* **99**:13723.
10. Takeda, K. *et al.* (1998) *Immunity* **8**:383.
11. Park, S. *et al.* (2007) *Cell. Mol. Immunol.* **4**:329.
12. Yoshimoto, T. *et al.* (1998) *J. Immunol.* **161**:3400.
13. Hoshino, T. *et al.* (2001) *J. Immunol.* **166**:7014.
14. Iannello, A. *et al.* (2009) *AIDS Rev.* **11**:115.
15. Rabkin, S.W. (2009) *Nat. Clin. Pract. Cardiovasc. Med.* **6**:192.
16. Netea, M.G. *et al.* (2006) *Nat. Med.* **12**:650.